Literature DB >> 17199569

Melanomas arising from naevi and de novo melanomas--does origin matter?

S C Weatherhead1, M Haniffa, C M Lawrence.   

Abstract

BACKGROUND: It is widely accepted that some melanomas arise from pre-existing naevi, while others appear de novo. The proportions involved and the effect of melanoma origin on prognosis is unclear.
OBJECTIVES: To determine whether melanomas reported by the patient to have developed from a pre-existing naevus are associated with a better or worse prognosis compared with those arising de novo when adjusted for confounding variables.
METHODS: All patients attending a dedicated melanoma screening clinic between March 1997 and March 2002 were included. The distinction between melanoma arising without any pre-existing lesion (de novo) and those derived from a pre-existing lesion (naevus melanoma) was based on patient history. We categorized patients into three groups: those who gave a history of their lesion arising within a pre-existing naevus, those in whom the melanoma developed de novo and those in whom no conclusive history could be obtained. We compared prognostic indicators between the naevus and de novo melanoma groups.
RESULTS: Of 8593 patients screened, 377 had a positive diagnosis of melanoma (in situ or invasive). Of these 42% had naevus melanomas, 34% new melanomas and 24% were uncertain. Patients presenting with a melanoma arising from a pre-existing naevus had a greater Breslow thickness despite presenting sooner than the de novo group, although no significant difference in thickness was found when other prognostic factors were controlled for.
CONCLUSIONS: This prospective study shows that naevi that undergo malignant change may result in melanomas that are thicker and thus potentially have a worse prognosis than de novo melanomas. Although our results were not statistically significant when other risk factors were also taken into account, it is possible that a larger study would identify a significant association.

Entities:  

Mesh:

Year:  2007        PMID: 17199569     DOI: 10.1111/j.1365-2133.2006.07570.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

Review 1.  Strategies for early melanoma detection: Approaches to the patient with nevi.

Authors:  Agnessa Gadeliya Goodson; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-05       Impact factor: 11.527

2.  Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma.

Authors:  Gabriel Salerni; Cristina Carrera; Louise Lovatto; Joan Anton Puig-Butille; Celia Badenas; Estel Plana; Susana Puig; Josep Malvehy
Journal:  J Am Acad Dermatol       Date:  2011-06-16       Impact factor: 11.527

3.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302

4.  De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.

Authors:  Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky
Journal:  J Natl Cancer Inst       Date:  2016-05-27       Impact factor: 13.506

5.  Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Mark Hyde; Glen M Bowen; Douglas Grossman
Journal:  Dermatol Surg       Date:  2010-07       Impact factor: 3.398

6.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

7.  Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Authors:  Linda Gao; Karin van den Hurk; Peter T M Moerkerk; Jelle J Goeman; Samuel Beck; Nelleke A Gruis; Joost J van den Oord; Véronique J Winnepenninckx; Manon van Engeland; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

Review 8.  Progress in understanding melanoma propagation.

Authors:  Mark Shackleton; Elsa Quintana
Journal:  Mol Oncol       Date:  2010-06-23       Impact factor: 6.603

9.  RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Nguyen Dinh Thang; Yuji Goto; Kozue Takeda; Osamu Yamanoshita; Machiko Iida; Nobutaka Ohgami; Haruka Tamura; Yoshiyuki Kawamoto; Masashi Kato
Journal:  Dermatol Res Pract       Date:  2011-10-12

10.  Merlin is a negative regulator of human melanoma growth.

Authors:  Lucas B Murray; Ying-Ka Ingar Lau; Qin Yu
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.